{
  "id": 28215,
  "title": "Africa: South Africa's Next HIV Battle Isn't About Science, It's About Access",
  "url": "https://urgent.news/2026/07/29/africa-south-africas-next-hiv-battle-isnt-about-science-its-about",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-29T06:54:27.000Z",
  "source": {
    "name": "AllAfrica Health",
    "slug": "allafrica-health",
    "url": "https://allafrica.com/stories/202607290006.html"
  },
  "original_language": "en",
  "account": "South Africa, the epicenter of the global HIV epidemic, is testing a new HIV prevention method: a twice-yearly injection called lenacapavir. This long-acting injection has shown almost complete protection against HIV and requires only two doses annually, offering an alternative to daily pills that many struggle to consistently take. With an estimated eight million people living with HIV in South Africa and about 160,000 new infections each year, researchers believe lenacapavir could revolutionize HIV prevention, especially for vulnerable groups like adolescent girls and young women. South Africa recently became the ninth African country to introduce lenacapavir into its public HIV prevention services, launching the program across six provinces in June. However, the rollout is occurring at a challenging time, with international HIV funding under pressure and civil society warning of the impact of cuts to U.S.-backed programs. During the International AIDS Society's AIDS 2026 conference in Rio de Janeiro, scientists, policymakers, pharmaceutical companies, and community advocates emphasized that while the science has advanced rapidly, access remains the critical issue. Beatriz Grinsztejn, President of the International AIDS Society, stressed that innovation without access is injustice, highlighting the urgent need to ensure that the new HIV prevention options reach those who need them most. South Africa's government is making strides to expand access to lenacapavir as part of its integrated HIV prevention strategy, but funding pressures from shrinking international health budgets may pose significant challenges.",
  "summary": "[allAfrica] Rio de Janeiro, Brazil -- For decades, South Africa has been at the epicentre of the global HIV epidemic. Today, it is becoming the testing ground for what many scientists believe could be the most important advance in HIV prevention since daily pre-exposure prophylaxis (PrEP): a twice-yearly injection that has shown almost complete protection against HIV.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}